Does the media favor ZYME or RYTM?

In the previous week, Rhythm Pharmaceuticals had 13 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, SRRK or ZYME?

Zymeworks has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Zymeworks $105.96M 17.79 -$81.13M -$2.02 N/A

Is SRRK or ZYME more profitable?

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Zymeworks -405.31% -72.30% -37.18%

Does the media refer more to SRRK or ZYME?

In the previous week, Scholar Rock had 29 more articles in the media than Zymeworks. MarketBeat recorded 33 mentions for Scholar Rock and 4 mentions for Zymeworks. Scholar Rock's average media sentiment score of 0.77 beat Zymeworks' score of 0.69 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 14 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZYME or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Mirum Pharmaceuticals' score of 0.62 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ZYME or CGON?

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 17.79 -$81.13M -$2.02 N/A CG Oncology $4.04M 1,637.21 -$160.99M -$2.69 N/A

Is ZYME or CGON more profitable?

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor ZYME or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Zymeworks. CG Oncology's average media sentiment score of 0.82 beat Zymeworks' score of 0.69 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZYME or TVTX?

In the previous week, Travere Therapeutics had 33 more articles in the media than Zymeworks. MarketBeat recorded 37 mentions for Travere Therapeutics and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Travere Therapeutics' score of 0.25 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 16 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zymeworks (ZYME) Competitors

$26.57 -0.91 (-3.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$26.58 +0.00 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Compare

ZYME vs. RYTM, SRRK, MIRM, CGON, and TVTX

Should you buy Zymeworks stock or one of its competitors? Zymeworks's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zymeworks compare to Rhythm Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Zymeworks has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 13 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Zymeworks currently has a consensus price target of $41.00, suggesting a potential upside of 54.31%. Rhythm Pharmaceuticals has a consensus price target of $140.67, suggesting a potential upside of 43.96%. Given Zymeworks' higher possible upside, equities analysts clearly believe Zymeworks is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zymeworks has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A

Summary

Zymeworks beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Zymeworks	-405.31%	-72.30%	-37.18%

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Scholar Rock currently has a consensus target price of $66.00, indicating a potential upside of 41.48%. Zymeworks has a consensus target price of $41.00, indicating a potential upside of 54.31%. Given Zymeworks' higher possible upside, analysts plainly believe Zymeworks is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.00
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Zymeworks has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A

In the previous week, Scholar Rock had 29 more articles in the media than Zymeworks. MarketBeat recorded 33 mentions for Scholar Rock and 4 mentions for Zymeworks. Scholar Rock's average media sentiment score of 0.77 beat Zymeworks' score of 0.69 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	14 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zymeworks beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Mirum Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Mirum Pharmaceuticals' score of 0.62 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zymeworks presently has a consensus target price of $41.00, suggesting a potential upside of 54.31%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 49.53%. Given Zymeworks' higher possible upside, analysts clearly believe Zymeworks is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Zymeworks has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A

Mirum Pharmaceuticals has a net margin of -139.18% compared to Zymeworks' net margin of -405.31%. Mirum Pharmaceuticals' return on equity of -36.28% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Zymeworks on 10 of the 17 factors compared between the two stocks.

How does Zymeworks compare to CG Oncology?

Zymeworks (NASDAQ:ZYME) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, CG Oncology had 3 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Zymeworks. CG Oncology's average media sentiment score of 0.82 beat Zymeworks' score of 0.69 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Zymeworks presently has a consensus target price of $41.00, suggesting a potential upside of 54.31%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 17.63%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Zymeworks has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A

Summary

Zymeworks beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Travere Therapeutics?

Zymeworks (NASDAQ:ZYME) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Travere Therapeutics has higher revenue and earnings than Zymeworks. Travere Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

Zymeworks has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Travere Therapeutics has a net margin of -7.35% compared to Zymeworks' net margin of -405.31%. Travere Therapeutics' return on equity of -55.15% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, Travere Therapeutics had 33 more articles in the media than Zymeworks. MarketBeat recorded 37 mentions for Travere Therapeutics and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.69 beat Travere Therapeutics' score of 0.25 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	16 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zymeworks presently has a consensus price target of $41.00, indicating a potential upside of 54.31%. Travere Therapeutics has a consensus price target of $68.00, indicating a potential upside of 8.35%. Given Zymeworks' higher possible upside, equities analysts plainly believe Zymeworks is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Zymeworks and Travere Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-13.15	14.30	275.79	25.40
Price / Sales	17.79	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	7.40	15.45	10.46	6.33
Net Income	-$81.13M	-$22.86M	$3.49B	$358.33M
7 Day Performance	1.26%	-1.21%	0.59%	1.12%
1 Month Performance	-2.35%	-4.42%	-2.01%	-2.67%
1 Year Performance	63.51%	37.81%	18.09%	6.01%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	2.9098 of 5 stars	$26.57 -3.3%	$41.00 +54.3%	+61.1%	$1.95B	$105.96M	N/A	264	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.7793 of 5 stars	$104.71 +2.5%	$141.12 +34.8%	-0.8%	$7.00B	$189.76M	N/A	414	News Coverage Analyst Forecast
SRRK Scholar Rock	3.6695 of 5 stars	$55.41 -0.5%	$58.77 +6.1%	+43.6%	$6.78B	N/A	N/A	289	Analyst Downgrade Analyst Revision Gap Down
MIRM Mirum Pharmaceuticals	3.0443 of 5 stars	$98.22 -2.4%	$137.31 +39.8%	+21.9%	$6.53B	$618.07M	N/A	433	Gap Up
CGON CG Oncology	2.852 of 5 stars	$72.35 +0.5%	$87.78 +21.3%	+92.2%	$6.38B	$6.23M	N/A	142

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, SRRK, MIRM, CGON, and TVTX

How does Zymeworks compare to Rhythm Pharmaceuticals?

Summary

How does Zymeworks compare to Scholar Rock?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Summary

How does Zymeworks compare to CG Oncology?

Summary

How does Zymeworks compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, SRRK, MIRM, CGON, and TVTX

How does Zymeworks compare to Rhythm Pharmaceuticals?

Which has more volatility & risk, ZYME or RYTM?

Does the media favor ZYME or RYTM?

Is ZYME or RYTM more profitable?

Do analysts prefer ZYME or RYTM?

Do insiders & institutionals hold more shares of ZYME or RYTM?

Which has better valuation & earnings, ZYME or RYTM?

Summary

How does Zymeworks compare to Scholar Rock?

Is SRRK or ZYME more profitable?

Do institutionals & insiders have more ownership in SRRK or ZYME?

Which has more volatility and risk, SRRK or ZYME?

Do analysts rate SRRK or ZYME?

Which has higher earnings & valuation, SRRK or ZYME?

Does the media refer more to SRRK or ZYME?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Does the media favor ZYME or MIRM?

Do insiders and institutionals have more ownership in ZYME or MIRM?

Do analysts rate ZYME or MIRM?

Which has more risk and volatility, ZYME or MIRM?

Which has higher valuation and earnings, ZYME or MIRM?

Is ZYME or MIRM more profitable?

Summary

How does Zymeworks compare to CG Oncology?

Does the media favor ZYME or CGON?

Is ZYME or CGON more profitable?

Do analysts prefer ZYME or CGON?

Which has more volatility and risk, ZYME or CGON?

Do institutionals and insiders have more ownership in ZYME or CGON?

Which has stronger valuation and earnings, ZYME or CGON?

Summary

How does Zymeworks compare to Travere Therapeutics?

Which has better valuation and earnings, ZYME or TVTX?

Which has more volatility & risk, ZYME or TVTX?

Is ZYME or TVTX more profitable?

Does the media refer more to ZYME or TVTX?

Do insiders and institutionals believe in ZYME or TVTX?

Do analysts recommend ZYME or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools